In this study, we developed PAR1-targeted CAR-T cells using third-generation CARs containing additional signaling domains, including CD28, CD137 (4-1BB), and CD3ζ (CD247), to augment activation of cytokine production and a tumor-eradication ability [38, 53]. The gene discussed is TNFRSF9; the disease is neoplasm.